

ERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

ABSTRACT

5 Chemical entities that modulate PD kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

10 (Figure 1)